Introduction to the Analysis of Recurrent Events in Clinical Trials
DOI:
https://doi.org/10.52787/agl.v53i4.365Keywords:
Reccurrent Events, methodsAbstract
In clinical trials where the aim lies in observing the occurrence of new events during the follow-up period, the main focus is usually on the time elapsed until the initial event occurs. If this initial event is non-fatal, adopting this approach means that information from subsequent incidents will be lost. However, when capturing the effect of treatment on the total burden of disease is of interest, it is recommended to include recurrent events into analysis. Recurrent events are defined as endpoints that occur after the initial event, as determined by researchers. Examples include readmissions, undergoing specific procedures, clinical worsening, and death during the follow-up period.
References
-1. Gregson J, Stone GW, Bhatt DL, Packer M, Anker SD, Zeller C, Redfors B, Pocock SJ. Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Oct 3;82(14):1445-1463. DOI: 10.1016/j.jacc.2023.07.024
-2. Arno Fritsch, Patrick Schlömer, Franco Mendolia, Tobias Mütze, Antje Jahn- Eimermacher & on behalf of the Recurrent Event Qualification Opinion Consortium (2021): Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Events-Application to Clinical Trials in Chronic Heart Failure, Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1945488
-3. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. DOI: 10.1056/NEJMoa2107038
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Emiliano Rossi

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.










